OS Therapies Inc (NYSE:OSTX - Get Free Report) dropped 0.9% during mid-day trading on Monday . The stock traded as low as $2.99 and last traded at $2.99. Approximately 23,802 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 180,573 shares. The stock had previously closed at $3.02.
Analyst Ratings Changes
A number of research firms recently weighed in on OSTX. Brookline Capital Management raised shares of OS Therapies to a "strong-buy" rating in a report on Thursday, August 22nd. EF Hutton Acquisition Co. I raised shares of OS Therapies to a "strong-buy" rating in a report on Tuesday, September 3rd.
Get Our Latest Stock Report on OSTX
OS Therapies Trading Up 0.3 %
The firm has a 50 day moving average price of $3.47.
OS Therapies (NYSE:OSTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. On average, equities analysts expect that OS Therapies Inc will post -0.47 EPS for the current year.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Featured Stories
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
